am 251 has been researched along with Anasarca in 1 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rodrigues, FF | 1 |
| Morais, MI | 1 |
| Melo, ISF | 1 |
| Augusto, PSA | 1 |
| Dutra, MMGB | 1 |
| Costa, SOAM | 1 |
| Costa, FC | 1 |
| Goulart, FA | 1 |
| Braga, AV | 1 |
| Coelho, MM | 1 |
| Machado, RR | 1 |
1 other study available for am 251 and Anasarca
| Article | Year |
|---|---|
Clindamycin inhibits nociceptive response by reducing tumor necrosis factor-α and CXCL-1 production and activating opioidergic mechanisms.
Topics: Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Behavior, Animal; Carrageenan; | 2020 |